Abstract
Adrenocortical carcinoma (ACC) is still one of the most devastating human tumors with a five year survival as low as 20 %. In a previous study, we showed that DNA vaccination followed by vaccinia virus was able to break immune tolerance against murine steroidogenic acute regulatory (mStAR). Prophylactic vaccination in syngenic mice resulted in protective immunity against Sp2-0 tumor cells expressing mStAR. However, approximately a third of the animals developed tumors despite vaccination. This prompted us to investigate whether vaccination failure is responsible for this phenomenon. BALB/cBALB/c mice (in groups of 6 - 9 animals) were vaccinated intramuscularly by injection of cDNA expression vectors encoding mStAR three times at weekly intervals. This was followed by a recombinant vaccinia virus (rVV-mStAR) infection to boost immune response. Ten days after the last vaccination, Sp2-mStAR or parental Sp2-0 cells (as controls) were injected s. c. Tumor development was monitored by daily palpation. Approximately two weeks later, the animals were sacrificed and the spleens removed. After restimulation with the cell lines expressing mStAR, the splenocytes were tested for presence of mStAR self-reactive cytotoxic T-lymphocytes using ELISPOT analysis. With this approach, we were able to show that those animals protected from tumor growth had a specific T-cell response against StAR whereas mice without a specific T-cell response developed Sp2-mStAR tumors. Our data demonstrate that vaccination failure, probably due to the low antigenicity of mStAR, is responsible for tumor growth in our model system.
Key words
Adrenocortical carcinoma - Steroidogenic acute regulatory protein - Immunotherapy - Mouse - CTL - Tolerance
References
1
Soreide J A, Brabrand K, Thoresen S O.
Adrenal cortical carcinoma in Norway, 1970 - 1984.
World J Surg.
1992;
16
663-668
2
Beuschlein F, Reincke M, Karl M, Travis W D, Jaursch-Hancke C, Abdelhamid S, Chrousos G P, Allolio B.
Clonal composition of human adrenocortical neoplasms.
Cancer Res.
1994;
54
4927-4932
3
Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P.
Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications.
Genes Chromosomes Cancer.
2000;
28
145-152
4
Reincke M, Beuschlein F, Slawik M, Borm K.
Molecular adrenocortical tumourigenesis.
Eur J Clin Invest.
2000;
30 Suppl 3
63-68
5
Dackiw A P, Lee J E, Gagel R F, Evans D B.
Adrenal cortical carcinoma.
World J Surg.
2001;
25
914-926
6
Ng L, Libertino J M.
Adrenocortical carcinoma: diagnosis, evaluation and treatment.
J Urol.
2003;
169
5-11
7
Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson C E, Lindstedt S.
Cytotoxic treatment of adrenocortical carcinoma.
World J Surg.
2001;
25
927-933
8
Zenkert S, Schubert B, Fassnacht M, Beuschlein F, Allolio B, Reincke M.
Steroidogenic acute regulatory protein mRNA expression in adrenal tumours.
Eur J Endocrinol.
2000;
142
294-299
9
Ortmann D, Hausmann J, Beuschlein F, Schmenger K, Stahl M, Geissler M, Reincke M.
StAR-directed immunotherapy protects against tumor growth of StAR expressing Sp2 - 0 cells in a rodent adrenocortical carcinoma model.
Endocrinology.
2004;
145
1760-1766
10
Clark B, Wells J, King S, Stocco D.
The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR).
J Biol Chem.
1994;
269
28314-28322
11
Rice D A, Kirkman M S, Aitken L D, Mouw A R, Schimmer B P, Parker K L.
Analysis of the promoter region of the gene encoding mouse cholesterol side-chain cleavage enzyme.
J Biol Chem.
1990;
265
11 713-11 720
12
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker E B, Steinman R M, Enk A, Kampgen E, Schuler G.
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma.
J Exp Med.
1999;
190
1669-1678
13
Banchereau J, Palucka A K, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski K M, Bhardwaj N, Pineiro L, Steinman R, and F ay.
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Cancer Res.
2001;
61
6451-6458
14
Timmerman J M, Czerwinski D K, Davis T A, Hsu F J, Benike C, Hao Z M, Taidi B, Rajapaksa R, Caspar C B, Okada C Y, van Beckhoven A, Liles T M, Engleman E G, Levy R.
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Blood.
2002;
99
1517-1526
15
Heiser A, Coleman D, Dannull J, Yancey D, Maurice M A, Lallas C D, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J.
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
J Clin Invest.
2002;
109
409-417
16
Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum W A, Seissler J.
Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma.
Clin Endocrinol (Oxf).
2001;
55
271-277
17
Schott M, Feldkamp J, Schattenberg D, Seissler J, Scherbaum W A.
Dendritic cell immuno-therapy in disseminated parathyroid carcinoma [letter; comment].
Lancet.
1999;
353
1188-1189
18
Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum W A, Feldkamp J.
Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.
J Clin Endocrinol Metab.
2001;
86
4965-4969
19
Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum W A, Seissler J.
Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination.
Cancer Immunol Immunother.
2002;
51
663-668
Martin Reincke, M. D.
Medizinische Klinik - Innenstadt · Klinikum der LMU München
Ziemssenstr. 1 · 80336 München · Germany
Telefon: + 49 (89) 51 60 21 00
Fax: + 49 (89) 51 60 44 28 ·
eMail: martin.reincke@med.uni-muenchen.de